Clinical trial NCT00000870 - References

HIV Infections — A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

Citation(s)

•   Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires K, Sillers M, Mitsuyasu RT, Kilby JM
  Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest. 1999 May 15;103(10):1391-8.
•   Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Sillers M, Squires K, Chiz S, Nowak MA, Shaw GM, Bucy RP
  Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med. 1999 May 17;189(10):1545-54.
•   Mitsuyasu R, Pollard R, Gelman R, Weng D
  Prospective, randomized, controlled phase II study of highly active antiretroviral therapy (HAART) with continuous IV (CIV) or subcutaneous (SC) interleukin-2 (IL-2) in HIV-infected patients with CD4+counts of 50-350 cells/mm3: ACTG 328-final results at 84 weeks. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 17)
•   Reier A, Mitsuyasu RT
  Use of interleukin-2 in immunotherapy of human immunodeficiency virus infection. BioDrugs. 1998 Sep;10(3):215-25.

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

Details for clinical trial NCT00000870